Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewOptions for empagliflozin in combination therapy in type 2 diabetes mellitusDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesEmpagliflozinSpotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic reviewSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsNew and emerging drugs and targets for type 2 diabetes: reviewing the evidenceComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.A Review on the Relationship between SGLT2 Inhibitors and Cancer.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesManagement of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.The role of empagliflozin in the management of type 2 diabetes by patient profile.Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 DiabetesSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepirideAn overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsPopulation Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes MellitusThe renal effects of SGLT2 inhibitors and a mini-review of the literature.SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.Empagliflozin for the treatment of Type 2 diabetes.Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.Empagliflozin for the treatment of type 2 diabetes.Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options
P2860
Q24563917-8A676EAD-B7FC-4700-9F41-6BDA1D2E2BF3Q26745771-999B6B27-DBF7-4F9C-AA82-3110B2BDDE27Q26749281-A5F099AB-85B8-48E4-9751-A54630BFAE39Q26773311-FAA592C4-C85A-4831-8714-A993FB7EAE46Q28071386-17D72944-9E95-42D0-8FDD-1AE143A275A5Q28072765-756782B8-B7FE-45A8-8A1D-2CFEAAAE3132Q28085516-129665E8-67ED-4530-8CB5-62787575EE98Q28546797-9205BE12-270C-4D1C-8473-AA9F754EE42AQ28553482-869582C6-470C-40BE-A560-B1A08C0FA633Q30248634-54A6FFF2-814A-49FE-AA61-AF6010BBACE0Q33837017-2E318BA6-21D5-4BED-82AB-38BECAA3E741Q33890770-7F679366-2593-4605-9D01-B63C73DA6D2FQ34181385-3B4F7A5E-3EC4-495C-9EA6-095B43E1E181Q34198692-EC478C9F-EB1F-4E33-ADA3-56B1E952AC0BQ34457919-1BA99EB4-B035-4ED4-BD3E-8497FB90CDA7Q34635575-BD3B0D70-9B92-4F74-A3EC-6A9F16B50939Q35157497-1146F44F-26C8-4AAB-AC1B-058121A1389BQ35592873-2D90EE4E-7F55-4358-A7C6-E8A8FFEB6D39Q35669990-5B23AC3C-A3E1-493F-9E6B-47AA670BCEECQ35906490-98992A5B-D882-4723-92C3-FEE5A95B32AFQ35911236-462999CB-65A6-49B4-91EC-85DB2D3FE4A9Q36823710-510A5D61-63CA-46A2-9409-4FB539532F57Q37114983-EE557CEF-14B9-42E9-B6ED-FDD7DE97CE5BQ37239278-CF655D27-53E0-43B2-9CC3-F78C793AB1CCQ37331262-FCD996F3-E989-44A1-AA77-5B3D88561292Q37351709-6127E67F-5B13-4E5A-990C-5A28326DED86Q37427304-E26F0257-B520-4AC7-8877-9625DD8C73D0Q37468412-9B29F3DD-D2B2-4465-A3DD-F4A2C993CE90Q37632127-619556B6-E6EF-49DF-8AA8-F288F85D6A87Q38176145-E5AA5226-17FD-4F22-8767-0D9FA742DF46Q38201162-B96F1CA5-2BDC-452A-8750-E2B8407FD761Q38203327-8E60F509-07E8-4366-8686-4522BE25D180Q38205581-F83BE8BF-BDCD-4474-85B6-7F6AF27F1280Q38250445-D8C0657B-96AF-4737-A8F5-289CBE22E3B1Q38254252-24E0E5AD-070F-48C6-926C-44C475110704Q38255999-684483C0-A6CA-4CEE-93A0-2BC4D8C4BCD0Q38258643-7299AE5D-F83F-413D-8E3A-EA162019ADF0Q38353558-6C306363-3115-4F7A-93F5-E74266A82A57Q38364908-A468D224-806F-4809-9FC2-6158BAEA980DQ38452883-20D9BB5B-F2ED-446E-BBDD-AD42067EF943
P2860
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Efficacy and safety of empagli ...... etes with mild hyperglycaemia.
@en
Efficacy and safety of empagli ...... etes with mild hyperglycaemia.
@nl
type
label
Efficacy and safety of empagli ...... etes with mild hyperglycaemia.
@en
Efficacy and safety of empagli ...... etes with mild hyperglycaemia.
@nl
prefLabel
Efficacy and safety of empagli ...... etes with mild hyperglycaemia.
@en
Efficacy and safety of empagli ...... etes with mild hyperglycaemia.
@nl
P2093
P2860
P921
P356
P1476
Efficacy and safety of empagli ...... etes with mild hyperglycaemia.
@en
P2093
H J Woerle
J Rosenstock
S Pinnetti
P2860
P304
P356
10.1111/DOM.12185
P577
2013-08-22T00:00:00Z